Acute Heart Failure - Pipeline Review, H2 2016

Date: July 13, 2016
Pages: 70
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: ABDA54744BAEN
Leaflet:

Download PDF Leaflet

Acute Heart Failure - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Acute Heart Failure - Pipeline Review, H2 2016’, provides an overview of the Acute Heart Failure pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acute Heart Failure, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Heart Failure and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Acute Heart Failure
  • The report reviews pipeline therapeutics for Acute Heart Failure by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Acute Heart Failure therapeutics and enlists all their major and minor projects
  • The report assesses Acute Heart Failure therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Acute Heart Failure
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Acute Heart Failure
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Acute Heart Failure pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Acute Heart Failure Overview
Therapeutics Development
Pipeline Products for Acute Heart Failure - Overview
Acute Heart Failure - Therapeutics under Development by Companies
Acute Heart Failure - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Acute Heart Failure - Products under Development by Companies
Acute Heart Failure - Companies Involved in Therapeutics Development
Amgen Inc.
Capricor Therapeutics, Inc.
Eli Lilly and Company
Lee's Pharmaceutical Holdings Limited
Novartis AG
Ono Pharmaceutical Co., Ltd.
PhaseBio Pharmaceuticals, Inc.
Trevena, Inc.
Acute Heart Failure - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
cenderitide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
istaroxime - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
omecamtiv mecarbil MR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ONO-4232 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PB-1046 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ruboxistaurin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
serelaxin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TRV-120023 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ularitide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Acute Heart Failure - Dormant Projects
Acute Heart Failure - Discontinued Products
Acute Heart Failure - Product Development Milestones
Featured News & Press Releases
Dec 11, 2015: Cardiorentis' Ularitide Receives FDA Fast Track Designation for the Treatment of Acute Decompensated Heart Failure
May 22, 2015: Cardiorentis Completes Enrollment in Pivotal Phase III Clinical Trial of Ularitide for Acute Heart Failure
Oct 16, 2014: Cardiorentis AG and Roche Announce Collaboration to Establish Therapeutic Impact of Ularitide
Oct 09, 2014: Capricor Therapeutics Announces Plans to Pursue a Cenderitide Clinical Program and Enters Into Research Support Agreement With Insulet Corporation
May 23, 2014: Novartis provides update on EU marketing authorization application for RLX030 in acute heart failure
May 16, 2014: FDA issues Complete Response Letter for RLX030 for acute heart failure
Mar 27, 2014: Novartis to work with FDA on path forward for RLX030 for acute heart failure following Advisory Committee outcome
Mar 25, 2014: FDA Staff Says Novartis’ Serelaxin Shouldn’t Be Approved
Jan 24, 2014: Novartis Europharm's Reasanz Receives CHMP Negative Opinion
Jan 24, 2014: Novartis to request re-examination of serelaxin in acute heart failure for conditional marketing authorization in EU
Dec 02, 2013: Paladin Announces Filing of New Drug Submission for RLX030 (Serelaxin)
Sep 03, 2013: Amgen And Cytokinetics Announce The First Presentation Of Data From Phase 2 ATOMIC-AHF Study Of Omecamtiv Mecarbil
Sep 02, 2013: Novartis' serelaxin improved symptoms and mortality across multiple subgroups of patients with acute heart failure
Jun 21, 2013: Novartis's Serelaxin Receives FDA Breakthrough Therapy Designation For Acute Heart Failure
Mar 18, 2013: Cytokinetics Announces Update To Heart Failure Program
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Acute Heart Failure, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Acute Heart Failure - Pipeline by Amgen Inc., H2 2016
Acute Heart Failure - Pipeline by Capricor Therapeutics, Inc., H2 2016
Acute Heart Failure - Pipeline by Eli Lilly and Company, H2 2016
Acute Heart Failure - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016
Acute Heart Failure - Pipeline by Novartis AG, H2 2016
Acute Heart Failure - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016
Acute Heart Failure - Pipeline by PhaseBio Pharmaceuticals, Inc., H2 2016
Acute Heart Failure - Pipeline by Trevena, Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Acute Heart Failure - Dormant Projects, H2 2016
Acute Heart Failure - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Acute Heart Failure, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Ask Your Question

Acute Heart Failure - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: